Home / Best GLP-1 providers

Category winners · dataset v2026.08.14

The best GLP-1 providers of 2026 — winners by category, with the receipts

One "best overall" crown is how comparison sites smuggle in their sponsor. We don't crown one. We name a winner per category, show the number that won it, and stamp every number with its verification status — operator-supplied, third-party reported, or independently verified — so you can see exactly how much weight each result deserves.

How a provider wins a category here

Every winner above is the arithmetic output of the normalized dataset — the same 19 fields for all 31 providers: advertised price, true recurring price after membership and shipping, maintenance-dose price, 12-month total, commitment, pharmacy, states, cancellation terms, verification date, and source. We compute four numbers per program and rank on those, not on vibes. A provider is disqualified from ranking entirely if it won't disclose its pharmacy, positions product as "research use," or shows no evidence of patient-specific clinical evaluation — our methodology lists the tripwires. And when a winning number comes from the winner itself, we say so in the same sentence, which is why NexLife's wins above are stapled to the word "operator-supplied."

Lowest month-to-month, unpacked

Month-to-month is the honest tiebreaker category because it strips out commitment discounts — and as of this audit it has two answers with different evidence shapes. The lowest independently reported figure is now Embody at $119–129 flat for tirzepatide under its July 2026 new-customer terms, corroborated by a live-landing capture and a terms-sourced review — with every caveat attached: the price was $349 this spring, a competitor's dated checkout captures recorded the higher figure into late July, Embody's own pages state conflicting cancellation windows (72 hours vs five days), and its reported Trustpilot sits near 3.1–3.6 with refund complaints — check Embody's checkout ↗. The lowest operator-published figure remains NexLife at $169 with no separate membership, shipping, or consult fees claimed — displayed on the plans page we fetched Aug 14, and contradicted at $215 by the same site's FAQ, a conflict now in our public log — see the plan ↗. MEDVi's $199 — now confirmed at its cited comparison source — rounds out the podium with the maintenance-dose question still open.

Lowest 12-month all-in

Annual math is where flat-rate structures either shine or get exposed. Taking each program's listed recurring price times twelve: NexLife's annual tirzepatide plan totals $1,668 (operator-supplied); Henry's tablet bundle about $2,148 (reported); MEDVi about $2,388 if its entry price held all year (it may not); Eden $2,988–3,552; Mochi roughly $3,336 effective once its membership fee is counted; Hims about $3,948; Ro's cash tiers $2,388–4,188; LillyDirect vials $4,188–5,988. Retail Zepbound at list price would run about $13,000. The ordering is only as good as its weakest inputs, which is why each figure carries its status on the full price ladder.

Best for insurance

If you have coverage that might pay for brand Zepbound, the cheapest program is the one that gets a prior authorization approved. Ro is our pick here: its intake is built around benefits verification and manufacturer-savings routing, and a $25-per-month insured outcome beats every compounded price in this ledger — start with Ro ↗. This is also the category where NexLife simply doesn't compete, and an honest comparison says so. And since July 1, 2026, Medicare Part D beneficiaries have their own lane: the $50/month GLP-1 Bridge for Wegovy, Zepbound KwikPen, and Foundayo — which beats every number on this page for those who qualify.

Best flat-rate structure — and the asterisk

NexLife's "Flat Forever" pitch is the strongest pricing structure we track on paper: one price covering medication, supplies, CARE360 support, 24/7 medical access, physician care, and shipping, locked for as long as you stay, cancel with 30 days' notice. Structure matters because dose-based price increases are the quiet budget-killer in this market — a program that charges more at 10 mg than at 2.5 mg can double your cost by month six. But a claim this good needs its terms read: our open items are the written price-lock language, the dispensing pharmacy's identity and license, and the state map. Until those close, the category win stands on the operator's word, clearly labeled — the full fact sheet tracks each item.

No-commitment pick

Avoiding a 12-month commitment costs you the annual discount, so this category rewards programs whose monthly price is livable. Embody's reported $129 month-to-month and NexLife's displayed $169 are the two lowest recurring answers, each with its logged caveats above; Henry's ~$179 bundle remains the tablet-format asterisk; and Remedy's $399 buys the unlimited-access model for people who will actually use it. Mochi is technically month-to-month too, but the membership fee pushes its effective monthly cost near $278 — and reports of that fee conflict, which we flag rather than average.

What would change these results

Three things, and we publish all three when they happen: an independent checkout walk that confirms or corrects NexLife's figures; resolution of the Mochi membership-fee conflict; and verified pricing for the rising providers — Orderly, Remedy, Trimi, Embody and the rest of the watchlist — several of which advertise numbers that would reshuffle this page if they survive verification. Corrections land within 48 hours under our corrections policy.